Tirzepatide dosage: what the label and the trials document

The short version

Tirzepatide is given as a once-weekly subcutaneous injection (an injection under the skin). The FDA label documents a starting dose of 2.5 mg once weekly for 4 weeks, then an increase to 5 mg, with further optional increases every 4 weeks in 2.5 mg steps up to a maximum of 15 mg. The three maintenance doses tested in the large SURPASS and SURMOUNT trials are 5 mg, 10 mg, and 15 mg. The drug stays in the body for about 5 days on average (the elimination half-life), which is what allows once-weekly dosing to maintain steady blood levels. Injections go into the thigh, abdomen, or upper arm. The biggest thing to know about tirzepatide dosage: the escalation is slow by design. Jumping doses too quickly is the main driver of nausea and GI side effects.

Tirzepatide dosage

The tirzepatide dosage schedule as documented in the FDA prescribing information ^[16]:

• Starting dose: 2.5 mg once weekly subcutaneously (4 weeks)
• First increase: 5 mg once weekly (4 weeks)
• Optional further increases in 2.5 mg increments every 4 weeks as tolerated:
• 7.5 mg → 10 mg → 12.5 mg → 15 mg
• Maximum maintenance dose: 15 mg once weekly

The three doses used across the SURPASS and SURMOUNT phase 3 programmes were 5 mg, 10 mg, and 15 mg once weekly. The 20-week escalation schedule used in SURMOUNT trials (2.5 mg → 5 mg → 7.5 mg → 10 mg → 12.5 mg → maintenance at 10 or 15 mg) is the schedule most commonly referenced in trial publications ^[4][5].

Doses are described here as documented in the FDA label and clinical-trial literature. Prescribing decisions, dose selection, and titration are the province of the treating physician.

Tirzepatide dose

Dose-response relationship. In SURPASS-1 through -5, higher doses produced larger HbA1c and body weight reductions in a dose-dependent pattern ^{[8][3][10][11]}. In SURMOUNT-1, mean weight change at 72 weeks was -15.0% at 5 mg, -19.5% at 10 mg, and -20.9% at 15 mg versus -3.1% with placebo ^[4]. This dose-response relationship was consistent across the trial programme.

Maximum tolerated dose in obesity trials. SURMOUNT-5 compared maximum tolerated doses of tirzepatide (10 or 15 mg) versus maximum tolerated doses of semaglutide (1.7 or 2.4 mg). Tirzepatide produced -20.2% weight loss versus -13.7% ^[5].

Why the slow escalation. The stepwise escalation schedule is designed to manage gastrointestinal tolerability. Nausea, vomiting, and diarrhoea are dose-related and most frequent during escalation. Clinical trial data showed these effects were mostly mild to moderate and typically eased with continued exposure at each dose level ^[4][14].

Pharmacokinetics: half-life and absorption

The elimination half-life of tirzepatide is approximately 5 days in humans ^[1]. This long half-life is the consequence of the C20 fatty-diacid modification (the eicosanedioic acid arm attached to the GIP-backbone peptide via a glutamic acid linker), which confers high albumin affinity. Once bound to albumin in the blood, the drug is protected from rapid clearance, producing a long-acting profile consistent with once-weekly dosing.

A Phase 1 programme in 142 subjects (healthy volunteers and people with type 2 diabetes) characterised the pharmacokinetics supporting once-weekly administration ^[1]. The fatty-diacid modification also delays gastric emptying — a property that peaks in the first weeks of treatment and attenuates with continued dosing ^[23].

For the perioperative setting: the ~5-day half-life means the drug is still active for approximately five half-lives (roughly 25 days) after the last dose. Because of slowed gastric motility, clinicians have raised the question of prolonged fasting or point-of-care gastric assessment around procedures — an active area of guidance development ^[22].

Administration: route and injection sites

Subcutaneous injection is the only route studied and approved in the clinical trial programme ^[1][16]. Injections are administered in the thigh, abdomen, or upper arm. Marketed formulations are refrigerated; specific storage parameters are formulation-dependent and outside the scope of the published efficacy literature.

The tirzepatide injection page covers what the research shows about the subcutaneous route, absorption characteristics, and the injection schedule from the label and trial protocols.

No oral formulation of tirzepatide has been approved; the once-weekly subcutaneous route is the product of the PK programme that established the albumin-binding design.